Abstract
The original version of this article unfortunately contained an error. In the Conflict of interest statement, Anne-Marie Quinson is described as declaring no conflict of interest.
- Title
- Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (vol 32, pg 861, 2020)
- Creators - without role
- Frank Kroschinsky - TU DresdenJan Moritz Middeke - TU DresdenMartin Janz - Max Delbrück Center for Molecular MedicineGeorg Lenz - University Hospital MünsterMathias Witzens-Harig - University Hospital HeidelbergReda Bouabdallah - Institute Paoli-CalmettesPaul La Rosee - An-Institut für Qualitätssicherung in der operativen MedizinAndreas Viardot - University Hospital UlmGilles Salles - Hôpital Lyon SudSeok Jin Kim - Samsung Medical CenterTae Min Kim - Seoul National UniversityOliver Ottmann - Cardiff UniversityJoerg Chromik - Goethe University FrankfurtAnne-Marie Quinson - Boehringer IngelheimUte von Wangenheim - Boehringer IngelheimUte Burkard - Boehringer IngelheimAndreas Berk - ClinTriCare GmbH & Co KG, Untere Illereicher Str 10, D-89281 Altenstadt, GermanyNorbert Schmitz - University Hospital Münster
- Publication Details
- Investigational new drugs, Vol.39(1), pp.285-286
- Publisher
- Springer Nature
- Number of pages
- 2
- Identifiers
- 9943876408331
- Academic Unit
- King Abdullah University of Science & Technology
- Language
- English
- Resource Type
- Journal article